Sera Prognostics Announces Conference Call and Webcast of Third Quarter 2021 Financial Results on November 9
Sera Prognostics (NASDAQ: SERA) will report its third quarter 2021 financial results on November 9, 2021, after market close. This announcement includes a conference call at 5:00 p.m. ET for discussing operational highlights and financial results. Sera Prognostics specializes in improving maternal and neonatal health through innovative pregnancy biomarker information, notably its PreTRM® test, which predicts preterm birth risk. The company aims to enhance healthcare while reducing costs through early intervention.
- Sera Prognostics focuses on innovative diagnostic tests to predict preterm birth risk, potentially improving maternal and neonatal health.
- Upcoming conference call allows stakeholders to gain insights into operational highlights and financial results.
- Company's revenues primarily derived from the PreTRM test, indicating potential vulnerability due to reliance on a single product.
- Forward-looking statements include risks such as net losses, cash generation concerns, and competition, which may impact future performance.
SALT LAKE CITY, Oct. 27, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter 2021 financial results on Tuesday, November 9, 2021, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.
Conference Call Details:
US domestic callers: (877) 870-4263
International callers: (412) 317-0790
Webcast Registration Link: https://www.webcaster4.com/Webcast/Page/2809/43385
Live audio of the webcast will be available online from the Investors page of the Company's website at www.seraprognostics.com. The webcast will be archived on the Investors page and will be available for one year.
About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to deliver early, pivotal information in pregnancy to physicians, enabling them to improve the health of their patients, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM® test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is located in Salt Lake City, Utah.
About the PreTRM® Test
The PreTRM® test, which is ordered by a medical professional, measures and analyzes proteins in the blood that are highly predictive of preterm birth.
Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc in the U.S. and/or other countries.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the date and time of the Company's quarterly earnings release and conference call; and the company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; the ongoing COVID-19 pandemic and its impact on our operations, as well as the business or operations of third parties with whom we conduct business; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Final Prospectus on Form S-1, which was filed with the Securities and Exchange Commission on July 14, 2021, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-announces-conference-call-and-webcast-of-third-quarter-2021-financial-results-on-november-9-301409177.html
SOURCE Sera Prognostics, Inc.
FAQ
When is Sera Prognostics' third quarter 2021 earnings report due?
What is the focus of Sera Prognostics?
What is the PreTRM test offered by Sera Prognostics?
What time will the Sera Prognostics conference call take place?
How does Sera Prognostics plan to address its reliance on the PreTRM test?
